Professor Sally Barrington

Biography

Sally Barrington trained in Nuclear Medicine at Guy’s and St Thomas’ Hospitals and was appointed as Consultant in Nuclear Medicine in 1998.  Her clinical experience encompasses all aspects of PET-CT including oncology, neurology, cardiology and infection/inflammation using a variety of tracers. She was appointed as a National Institute of Health Research (NIHR) Research Professor from 01 December 2017.  She is co-lead of the UK PET Research Network with Prof Paul Marsden based at the KCL and GSTT PET Imaging Centre at St Thomas'. Research interests - PET and lymphoma - Standardisation of PET and organisation of multicentre trials - PET and Radiotherapy planning Dr Barrington is the author of: International guidelines on the staging and response assessment of lymphoma European guidelines on the use of FDG in Tumour Imaging European and UK guidelines on the use of PET-CT in Children British Society of Haematology guidelines in Hodgkin and Diffuse Large B Cell Lymphoma She is involved in national and international multicentre trials in PET and lymphoma investigating response-adapted approaches and is a central reviewer for the following trials: PETReA - Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma IELSG 37 - A randomised, open-label, multicentre, two-arm phase III comparative study assessing the role of involved mediastinal radiotherapy after rituximab containing chemotherapy regimens to patients with newly diagnosed primary mediastinal B-Cell lymphoma (PMBL)  (International) BREVITY: A phase II study of brentuximab vedotin (SGN-35) using a response adapted design in patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity (UK) TORCH: Dual mTOR inhibition and PET based response in DLBCL – exploratory analysis within the TORCH phase II trial (UK) CARDAMON: Carfilzomib/Cyclophosphamide/Dexamethasone with maintenance carfilzomib in untreated transplant-eligible patients with symptomatic multiple myeloma to evaluate the benefit of upfront autologous stem cell transplant Other activities: Member of the Scientific Committee for international workshops on PET in lymphoma, European Lymphoma Institute (2010-current) Lecturer on European Society of Oncology Programme awarding the Certificate of Competence in lymphoma (2012-current) Editorial Board of Journal of Clinical Oncology (2013-current) Member of Administration of Radioactive Substances Advisory Committee (ARSAC) (2012- current) Member of CRUK Expert Review Panel Chair of the Radiation Safety Committee of Guy's and St Thomas' NHS Foundation Trust (2013-current) Member of Oncology Committee of the European Association of Nuclear Medicine (2013-2017) Grant collaborations beyond King's College London: A Pettitt SF Barrington et al. CRUK/16/017 PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma (PETReA) reference C18029/A21585 01/10/2016 - duration 98 months: £1,482,852.67 G Collins, SF Barrington et al Dual mTOR inhibition and PET based response in DLBCL – exploratory analysis within the TORCH phase II trial Leukaemia and Lymphoma Research 14029 (2015): £44,100 A Davies, SF Barrington et al CRUK/12/040: IELSG 37 - A randomised, open-label, multicentre, two-arm phase III comparative study assessing the role of involved mediastinal radiotherapy after rituximab containing chemotherapy regimens to patients with newly diagnosed primary mediastinal B-Cell lymphoma (PMBL)  01 May 2013 to 30 April 2022 CTAAC : C30423/A16247 £247,533 J Radford, SF Barrington et al  ""BREVITY: A phase II study of brentuximab vedotin (SGN-35) using a response adapted design in patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity"" (2012) Millenium £330,673